Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-CD147 PET Imaging in Solid Tumors
NCT04841421Phase 1Unknown
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of 89Zr-CD147 in solid tumor (3 arms), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Standardized Uptake Value, Standardized Uptake Value Ratio and 1 more. Status: unknown.
02
Drugs
89Zr-CD147
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04841421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841421.